Keros Therapeutics to Showcase Innovations at Key Events
Keros Therapeutics to Showcase Innovations at Key Events
Lexington-based Keros Therapeutics, Inc. (Nasdaq: KROS) is making strides in the biopharmaceutical field, focusing on innovative therapeutic solutions for patients grappling with disorders stemming from dysfunctional signaling of the transforming growth factor-beta (TGF-ß) protein family. Today, Keros announced that its Chair and CEO, Dr. Jasbir S. Seehra, will be participating in several upcoming healthcare conferences.
Upcoming Healthcare Conferences
TD Cowen 45th Annual Healthcare Conference
Join Keros at this leading event on Monday, March 3, 2025, where Dr. Seehra will deliver insights during a fireside chat starting at 9:50 a.m. Eastern time. Attendees will have a unique opportunity to learn more about Keros' innovative approaches in therapeutics.
Leerink Partners Global Healthcare Conference
Another chance to engage with Keros is at the Leerink Partners Global Healthcare Conference, slated for Monday, March 10, 2025, at 1:40 p.m. Eastern time. This conversational format promises to unveil further discussions about Keros' impactful research and development efforts.
Archived Presentations Accessible Online
For those unable to attend, Keros will provide archived replays of each presentation in the Investors section of their website, available for up to 90 days post-event. This ensures that all interested stakeholders can stay informed about the company’s ongoing initiatives and scientific advancements.
About Keros Therapeutics, Inc.
Keros is at the forefront of biopharmaceutical innovation, devoted to the discovery and commercialization of unique therapeutics that cater to a broad spectrum of disorders linked to TGF-ß protein signaling. This protein family plays a fundamental role in the regulation of growth, repair, and maintenance of various tissue types, which presents significant therapeutic potentials.
Among Keros' promising candidates is cibotercept (KER-012), aimed at treating pulmonary arterial hypertension and cardiovascular disorders. Another key candidate, KER-065, focuses on neuromuscular diseases, while elritercept (KER-050) addresses low blood cell counts, or cytopenias, including anemia and thrombocytopenia associated with myelodysplastic syndrome and myelofibrosis.
Investor Relations Contact
If you have any inquiries or require further information, please reach out to:
Justin Frantz
Email: jfrantz@kerostx.com
Phone: 617-221-6042
Frequently Asked Questions
What is Keros Therapeutics focused on?
Keros Therapeutics specializes in developing novel therapeutics aimed at treating disorders related to dysfunctional signaling of the TGF-ß protein family.
Who will represent Keros at the conferences?
Dr. Jasbir S. Seehra, the Chair and CEO of Keros, will be the representative at the upcoming healthcare conferences.
What are the dates of the scheduled conferences?
The TD Cowen conference is on March 3, 2025, and the Leerink Partners conference is on March 10, 2025.
Will the presentations be available later?
Yes, Keros will provide archived replays of the presentations on their website, accessible for 90 days after each event.
What are some of Keros' key product candidates?
Keros is developing several candidates, including cibotercept for pulmonary arterial hypertension and elritercept for low blood cell counts associated with specific disorders.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
